ICON Public Limited Company (ICLR) Stock Score, Valuation & Financial Research
ICON Public Limited Company is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 32/100.
Quick answer for ICLR
ICON Public Limited Company currently has a Wall Street Score of 32/100. The stored market price is $173.94. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is -1.8 points. These figures are a research snapshot, not a buy or sell recommendation.
What ICON Public Limited Company does
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufac
ICLR financial snapshot
- Wall Street Score:
- 32/100
- Current price:
- $173.94
- Market capitalization:
- $13.32B
- Revenue:
- $8.25B
- Net income:
- $328.9M
- Free cash flow:
- $862.0M
- Cash:
- $928.4M
- Total debt:
- $3.49B
- EPS:
- 2.92
- P/E ratio:
- 59.6x
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 11/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $862.0M, showing positive cash generation.
- The balance sheet shows $928.4M of cash versus $3.49B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -1.8 points: ICLR decreased 1.8 points because Capital declined by 3 points, Management declined by 15.1 points, Buffett declined by 2.4 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research ICLR
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.